Related Experiment Videos
Gene therapy for human malignant brain tumors.
1Department of Neurological Science, University of Liverpool, Liverpool L9 7LJ, UK. rainov@liv.ac.uk
Cancer Journal (Sudbury, Mass.)
|September 4, 2003
Summary
Gene therapy for brain tumors, particularly malignant glioma, has faced challenges due to low transduction rates. Despite setbacks in clinical trials, ongoing research improves vector systems and delivery methods for better efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Malignant brain tumors, especially glioma, exhibit unique biological features favorable for gene therapy.
- Gene therapy research for malignant glioma began in the late 1980s, progressing from laboratory studies to clinical trials.
Purpose of the Study:
- To investigate the role and efficacy of gene therapy in treating malignant glioma.
- To explore the potential of targeting unique brain tumor cell characteristics for therapeutic nucleic acid transfer.
Main Methods:
- Early research utilized retrovirus vectors for transduction and killing of glioma cells.
- Clinical trials involved retrovirus, adenovirus, and herpes simplex virus type 1-based vectors.
- Novel vector generations focus on genetically engineered, tumor-selective lytic properties.
Main Results:
- Retrovirus-mediated gene therapy showed a favorable safety profile and some efficacy in Phase I/II trials for recurrent glioma.
- A Phase III trial for primary malignant glioma did not demonstrate significant improvements in survival.
- Safety concerns limit the clinical use of adenovirus and herpes simplex virus type 1 vectors.
Conclusions:
- Low in vivo tumor cell transduction rates are a primary reason for the limited success of gene therapy in brain tumors.
- Vector delivery strategies and assessment criteria for clinical efficacy require further refinement.
- Despite challenges, clinical trials have significantly advanced vector systems, delivery methods, and treatment protocols for malignant glioma.